{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:21:22Z","timestamp":1767853282425,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T00:00:00Z","timestamp":1327017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and Aim:\u2002<\/jats:bold> The thiopurines azathioprine and 6\u2010mercaptopurine are effective in the management of patients with inflammatory bowel disease (IBD) in whom aminosalicylates, antibiotics and corticosteroids have failed to induce or maintain remission. Long\u2010term use of these agents has been linked to a greatly increased risk of non\u2010melanoma skin cancer and lymphatic cancer in organ transplant recipients. There is some evidence to suggest that IBD patients receiving thiopurines might be at increased risk of cancer. Our aim was to determine the incidence of cancer in a cohort of patients with IBD managed in our clinic, and to relate this to thiopurine exposure.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> We conducted a retrospective study based on the clinical and pathology records of patients attending a specialist IBD clinic at Groote Schuur Hospital, Cape Town, South Africa between 1960 and 2007.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> We analyzed the records of 1084 patients. A total of 123 subjects (11.5%) had received thiopurine therapy. Cancer was identified in 51 patients (4.7%), including colorectal cancer (15 patients), melanoma (two patients), non\u2010melanoma skin cancer (seven patients) and non\u2010Hodgkin's lymphoma (five patients). A diagnosis of non\u2010melanoma skin cancer was significantly associated with thiopurine exposure (odds ratio 5.0, 95% confidence interval 1.1\u201322.8). Six of seven non\u2010melanoma skin cancers occurred in Caucasian patients, with a highly significant association with thiopurine use (odds ratio 12.4, 95% confidence interval 2.3\u201367.4).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Patients with IBD who receive thiopurines are at increased risk of non\u2010melanoma skin cancer. The risk is highest in Caucasian patients, and is negligible in other groups.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2011.06865.x","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T04:02:32Z","timestamp":1311825752000},"page":"385-389","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non\u2010melanoma skin cancer in an at\u2010risk population: A cohort study"],"prefix":"10.1111","volume":"27","author":[{"given":"Mashiko","family":"Setshedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor A","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landon","family":"Myer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Watermeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hift","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1443-9573.2007.00287.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.5.674"},{"issue":"2","key":"e_1_2_5_4_2","article-title":"Azathioprine for maintaining remission of Crohn's disease","author":"Pearson DC","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"e_1_2_5_5_2","article-title":"Azathioprine or 6\u2010mercaptopurine for maintenance of remission in Crohn's disease","author":"Prefontaine E","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"e_1_2_5_6_2","article-title":"Azathioprine or 6\u2010mercaptopurine for inducing remission of Crohn's disease","author":"Sandborn W","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-0036-6"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000478.pub2"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199506270-00011"},{"key":"e_1_2_5_10_2","first-page":"1946","article-title":"Malignancy following renal transplantation","volume":"24","author":"Sheil AG","year":"1992","journal-title":"Transplant. Proc."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.02.016"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000108491.62935.DF"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07021.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.059"},{"key":"e_1_2_5_15_2","first-page":"S328","article-title":"Incidence and treatment of neoplasia after transplantation","volume":"12","author":"Penn I","year":"1993","journal-title":"J. Heart Lung Transplant."},{"key":"e_1_2_5_16_2","first-page":"1705","article-title":"Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases","volume":"26","author":"Asten P","year":"1999","journal-title":"J. Rheumatol."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90245-1"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6203.1461"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldl020"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.273.5278.1109"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2003.10.007"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1986.tb05602.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1114233"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2006.11.003"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200102000-00017"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910600309"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01297.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.4.514"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.4.462"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.11.024"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04330.x"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.049460"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H219"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20959"},{"key":"e_1_2_5_37_2","unstructured":"South African National Cancer Association.Summary Statistics of Cancer Diagnosed Histologically in 2001 [Internet]. Johannesburg: South African National Cancer Association;2010. Cited 29 March 2011. Available from URL:http:\/\/www.cansa.org.za\/cause_data\/images\/1056\/NCRTables_2001.pdf"},{"key":"e_1_2_5_38_2","unstructured":"Intersun Program.Ultraviolet Radiation and the INTERSUN Programme [Internet]. Geneva: World Health Organization;2011. Cited 29 March 2011. Available from URL:http:\/\/www.who.int\/uv\/intersunprogramme\/activities\/uv_index\/en\/index3.html"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5439.487"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206944"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2011.06865.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2011.06865.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:54:36Z","timestamp":1697345676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2011.06865.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,20]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1440-1746.2011.06865.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2011.06865.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,20]]},"assertion":[{"value":"2012-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}